Physician profile
Paul Wopperer
NPI 1346219847
$2,924.87
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $334 · 2021: $545 · 2022: $232 · 2023: $208 · 2024: $523 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.65 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $499.23 | 2019-2023 | |
| Astellas Pharma US INC | $450.15 | 2021-2025 | Veozah |
| Amgen INC. | $423.15 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $372.21 | 2021-2025 | |
| Therapeuticsmd, INC. | $286.86 | 2019-2022 | |
| Exact Sciences Corporation | $275.85 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $121.50 | 2021-2022 | |
| Abbvie INC. | $107.16 | 2019-2022 | |
| Radius Health, INC. | $72.22 | 2020-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $60.06 | 2019-2021 | |
| Daiichi Sankyo INC. | $53.43 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $46.49 | 2019 | |
| Agile Therapeutics, INC. | $42.65 | 2022-2023 | Twirla |
| Exeltis, USA INC. | $22.90 | 2025 | Slynd |
| Evofem Biosciences, INC. | $21.77 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $19.48 | 2019 | |
| Roche Diagnostics Corporation | $19.33 | 2021 | |
| Hologic Sales and Service, LLC | $18.40 | 2024 | Aptima |
| Amag Pharmaceuticals, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wopperer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.